Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico
Authors
Keywords
-
Journal
npj Vaccines
Volume 8, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-05-10
DOI
10.1038/s41541-023-00662-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
- (2022) Sandile Cele et al. NATURE
- SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
- (2022) Annika Rössler et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
- (2022) Peter B. Gilbert et al. SCIENCE
- Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
- (2022) Nick Andrews et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
- (2022) Juliet R. C. Pulliam et al. SCIENCE
- Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
- (2022) Alexander Wilhelm et al. EBioMedicine
- Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
- (2022) Irene González-Domínguez et al. Microbiology Spectrum
- Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
- (2021) Ting Zhao et al. Human Vaccines & Immunotherapeutics
- The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
- (2021) Ying Liu et al. JOURNAL OF TRAVEL MEDICINE
- Evidence for antibody as a protective correlate for COVID-19 vaccines
- (2021) Kristen A. Earle et al. VACCINE
- Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs
- (2021) Jesús Horacio Lara-Puente et al. mBio
- Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021
- (2021) Ashley Fowlkes et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
- (2021) Eli S. Rosenberg et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021
- (2021) Lin T. Brandal et al. Eurosurveillance
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
- (2021) Juan Manuel Carreño et al. NATURE
- The Evolutionary Landscape of SARS-CoV-2 Variant B.1.1.519 and Its Clinical Impact in Mexico City
- (2021) Alberto Cedro-Tanda et al. Viruses-Basel
- A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses
- (2021) Weina Sun et al. Nature Communications
- Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats
- (2021) Johnstone Tcheou et al. Frontiers in Immunology
- A pneumonia outbreak associated with a new coronavirus of probable bat origin
- (2020) Peng Zhou et al. NATURE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction
- (2020) Chee Wah Tan et al. NATURE BIOTECHNOLOGY
- Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
- (2020) Ching-Lin Hsieh et al. SCIENCE
- Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2
- (2020) Edris Shirvani et al. Pathogens
- SARS-CoV-2 vaccines in development
- (2020) Florian Krammer NATURE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Correlates of protection against SARS-CoV-2 in rhesus macaques
- (2020) Katherine McMahan et al. NATURE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global production capacity of seasonal and pandemic influenza vaccines in 2019
- (2020) Erin Sparrow et al. VACCINE
- Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate
- (2020) Weina Sun et al. EBioMedicine
- A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
- (2020) Weina Sun et al. Vaccines
- Induction of mucosal immunity through systemic immunization: Phantom or reality?
- (2016) Fei Su et al. Human Vaccines & Immunotherapeutics
- Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs
- (2012) Dongni Kong et al. VIROLOGY
- Recommendations for the validation of flow cytometric testing during drug development: II assays
- (2010) Denise M. O'Hara et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector
- (2010) J. Kortekaas et al. VACCINE
- Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
- (2009) A. C. Lowen et al. JOURNAL OF VIROLOGY
- Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans
- (2009) Joshua M. DiNapoli et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started